NEW YORK(GenomeWeb) – Vermillion said after the close of the market Tuesday that it has reached a new commercialization and services agreement with Quest Diagnostics.

Under the agreement, Vermillion will pay Quest an undisclosed sum and fees for logistical support services as Vermillion transitions its OVA1 ovarian cancer testing business from Quest to its own subsidiary, Aspira Labs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.